All In Biotech

Drug Trial Radar · NCT00548340

VEC-162 Study in Adult Patients With Primary Insomnia

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Investigate the Efficacy and Safety of VEC-162 (20 mg/Day and 50 mg/Day) in the Treatment of Primary Insomnia

Last checked: Nov 19, 2026Latest source record: Oct 15, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 322 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

322

Actual

Start

Nov 2007

Primary completion

Feb 2008

Study completion Jun 2008

Sponsor

Lead sponsor
Vanda PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Oct 23, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of a 5 week double-blind treatment period of VEC-162 as compared to placebo in male and female patients with primary insomnia.

Conditions

  • Primary Insomnia

Interventions

  • VEC-162 20 mgDrug

    20 mg VEC-162 (tasimelteon) capsules, PO daily for five weeks

  • PlaceboDrug

    Placebo capsules, PO daily for five weeks

  • VEC-162 50 mgDrug

    50 mg VEC-162 (tasimelteon) capsules, PO daily for five weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Average Change From Baseline - Latency to Persistent Sleep (LPS)Time frame: Baseline, Night 1, and Night 8 measurement

Locations

35 sites in 1 country. Site status is shown where the registry gives one.

  • Vanda Investigational Site

    Birmingham, Alabama

  • Vanda Investigational Site

    Hot Springs, Arkansas

  • Vanda Investigational Site

    Little Rock, Arkansas

  • Vanda Investigational Site

    Anaheim, California

  • Vanda Investigational Site

    Burbank, California

  • Vanda Investigational Site

    Los Angeles, California

  • Vanda Investigational Site

    San Diego, California

  • Vanda Investigational Site

    Santa Monica, California

  • Vanda Investigational Site

    Colorado Springs, Colorado

  • Vanda Investigational Site

    Hallandale, Florida

  • Vanda Investigational Site

    Miami, Florida

  • Vanda Investigational Site

    Naples, Florida

  • Vanda Investigational Site

    Orlando, Florida

  • Vanda Investigational Site

    Pembroke Pines, Florida

  • Vanda Investigational Site

    St. Petersburg, Florida

  • Vanda Investigational Site

    Atlanta, Georgia

  • Vanda Investigational Site

    Chicago, Illinois

  • Vanda Investigational Site

    Overland Park, Kansas

  • Vanda Investigational Site

    Crestview Hills, Kentucky

  • Vanda Investigational Site

    Lexington, Kentucky

  • Vanda Investigational Site

    Louisville, Kentucky

  • Vanda Investigational Site

    Chevy Chase, Maryland

  • Vanda Investigational Site

    Newton, Massachusetts

  • Vanda Investigational Site

    Troy, Michigan

  • Vanda Investigational Site

    Chesterfield, Missouri

  • Vanda Investigational Site

    Las Vegas, Nevada

  • Vanda Investigational Site

    New York, New York

  • Vanda Investigational Site

    West Seneca, New York

  • Vanda Investigational Site

    Raleigh, North Carolina

  • Vanda Investigational Site

    Beachwood, Ohio

  • Vanda Investigational Site

    Cincinnati, Ohio

  • Vanda Investigational Site

    Oklahoma City, Oklahoma

  • Vanda Investigational Site

    Columbia, South Carolina

  • Vanda Investigational Site

    Austin, Texas

  • Vanda Investigational Site

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.